EIPM Special Seminar: "Counting What Matters: Quantitative Spatial Proteomics for Complex Tissues" with James R. Mansfield

EIPM Special Seminar "Counting What Matters: Quantitative Spatial Proteomics for Complex Tissues" with James R. Mansfield VP Business Development Imaging, Standard BioTools Seminar: 1pm-2pm ET Q&A Session: 2pm-3pm ET Abstract: Biology is spatial, and spatial imaging methods are increasingly being asked to do more. Complex cell types like cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are defined by combinations of dozens of markers and graded expression levels, not simple on/off calls. Therapies such as antibody-drug conjugates (ADCs) add further layers: target expression, payload delivery, downstream pathway activation, and immune context all need resolving in the same tissue. Imaging Mass Cytometry (IMC) is ideal for this. It measures 40+ proteins in a single pass with no spectral overlap, and its linear dynamic range supports precise quantitation of both low- and high-abundance targets. IMC is also a simple choice for same-slide multiomics, layering protein data onto Xenium, MALDI, and/or H&E sections to connect transcript, metabolite, and morphology to protein function. Assay development is simple too. Staining uses a cocktail of primary antibodies, so panel development comes down to one all-markers-at-once titration, typically about a day. With nearly 300 validated antibodies in 30+ panels, including ADC panels with markers of downstream payload effects, and the ability to label any clone, new targets and pathway markers can be added quickly, even for complex cell types like CAFs and TAMs. This talk covers how these tools work together. IMC is already available at Weill Cornell through the Human Immune Monitoring Core, so getting started is simple. Biography: James R. Mansfield is a scientist with over 30 years of experience in biomedical imaging, with the past two decades focused on multiplex pathology and in situ immune cell phenotyping. He currently serves as Vice President of Imaging at Standard BioTools, where he leads efforts to advance the Hyperion Imaging System for high-dimensional tissue analysis. Prior to this, he was Senior Vice President at Visiopharm, where he helped develop the Phenoplex multiplex analysis platform. Earlier in his career, he managed the Vectra multiplex imaging system and inForm software at PerkinElmer, helping to establish core technologies now widely used in spatial biology. James is an associate editor of the American Journal of Nuclear Medicine and Molecular Imaging, holds seven patents, and has authored over 60 scientific publications. He is a frequent invited speaker and has served as a session chair and organizer at numerous international meetings in molecular imaging, digital pathology, and spatial omics.